ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
SAN DIEGO and NEW YORK and SINGAPORE, Dec. 20, 2023 (GLOBE NEWSWIRE) — ImmunoScape, a biotechnology company focused on the discovery and development of next-generation T cell receptor (TCR)-based therapeutics, and MiNK Therapeutics, Inc (Nasdaq:INKT), a clinical stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell targeting therapies, today announced a collaboration agreement to discover and develop next-generation TCR therapies against novel targets in solid tumors. The combined efforts of both companies aim to accelerate the development of TCR-based therapies against novel targets in T cells, iNKT cells, and other modalities, potentially offering new therapeutic approaches for diverse cancer indications.
Related news for (INKT)
- Into the Homestretch: Must-Watch Stocks Heading into After-Hours
- Stocks In Flight Roundup: July 11, 2025
- Key Biotech Developments Worth Watching
- MiNK Therapeutics Publishes Details of Complete Remission in Metastatic Testicular Cancer Following Allogeneic iNKT Cell Therapy
- MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients